vs

Side-by-side financial comparison of INTERNATIONAL BANCSHARES CORP (IBOC) and Oncology Institute, Inc. (TOI). Click either name above to swap in a different company.

INTERNATIONAL BANCSHARES CORP is the larger business by last-quarter revenue ($217.7M vs $142.0M, roughly 1.5× Oncology Institute, Inc.). INTERNATIONAL BANCSHARES CORP runs the higher net margin — 62.3% vs -5.3%, a 67.6% gap on every dollar of revenue. On growth, Oncology Institute, Inc. posted the faster year-over-year revenue change (41.6% vs 4.5%). INTERNATIONAL BANCSHARES CORP produced more free cash flow last quarter ($472.9M vs $2.2M). Over the past eight quarters, Oncology Institute, Inc.'s revenue compounded faster (22.5% CAGR vs 2.8%).

International Bancshares Corporation is a bank holding company based in Laredo, Texas whose primary subsidiary is International Bank of Commerce. Through its bank subsidiaries, it has 217 banking offices and 315 automated teller machines serving 88 communities in the U.S. states of Texas and Oklahoma.

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

IBOC vs TOI — Head-to-Head

Bigger by revenue
IBOC
IBOC
1.5× larger
IBOC
$217.7M
$142.0M
TOI
Growing faster (revenue YoY)
TOI
TOI
+37.0% gap
TOI
41.6%
4.5%
IBOC
Higher net margin
IBOC
IBOC
67.6% more per $
IBOC
62.3%
-5.3%
TOI
More free cash flow
IBOC
IBOC
$470.8M more FCF
IBOC
$472.9M
$2.2M
TOI
Faster 2-yr revenue CAGR
TOI
TOI
Annualised
TOI
22.5%
2.8%
IBOC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBOC
IBOC
TOI
TOI
Revenue
$217.7M
$142.0M
Net Profit
$106.9M
$-7.5M
Gross Margin
Operating Margin
62.8%
-4.9%
Net Margin
62.3%
-5.3%
Revenue YoY
4.5%
41.6%
Net Profit YoY
-7.1%
43.0%
EPS (diluted)
$1.71
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBOC
IBOC
TOI
TOI
Q4 25
$217.7M
$142.0M
Q3 25
$218.1M
$136.6M
Q2 25
$208.2M
$119.8M
Q1 25
$198.2M
$104.4M
Q4 24
$208.3M
$100.3M
Q3 24
$211.8M
$99.9M
Q2 24
$207.8M
$98.6M
Q1 24
$205.8M
$94.7M
Net Profit
IBOC
IBOC
TOI
TOI
Q4 25
$106.9M
$-7.5M
Q3 25
$108.4M
$-16.5M
Q2 25
$100.1M
$-17.0M
Q1 25
$96.9M
$-19.6M
Q4 24
$115.1M
$-13.2M
Q3 24
$99.8M
$-16.1M
Q2 24
$97.0M
$-15.5M
Q1 24
$97.3M
$-19.9M
Operating Margin
IBOC
IBOC
TOI
TOI
Q4 25
62.8%
-4.9%
Q3 25
62.6%
-5.9%
Q2 25
60.5%
-9.4%
Q1 25
61.1%
-9.5%
Q4 24
64.2%
-11.9%
Q3 24
60.0%
-13.9%
Q2 24
60.1%
-16.6%
Q1 24
59.9%
-19.0%
Net Margin
IBOC
IBOC
TOI
TOI
Q4 25
62.3%
-5.3%
Q3 25
49.7%
-12.1%
Q2 25
48.1%
-14.2%
Q1 25
48.9%
-18.8%
Q4 24
71.5%
-13.1%
Q3 24
47.1%
-16.1%
Q2 24
46.7%
-15.7%
Q1 24
47.3%
-21.0%
EPS (diluted)
IBOC
IBOC
TOI
TOI
Q4 25
$1.71
$-0.04
Q3 25
$1.74
$-0.14
Q2 25
$1.61
$-0.15
Q1 25
$1.56
$-0.21
Q4 24
$1.85
$-0.14
Q3 24
$1.60
$-0.18
Q2 24
$1.56
$-0.17
Q1 24
$1.56
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBOC
IBOC
TOI
TOI
Cash + ST InvestmentsLiquidity on hand
$5.5B
Total DebtLower is stronger
Stockholders' EquityBook value
$3.3B
$-15.7M
Total Assets
$16.6B
$164.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBOC
IBOC
TOI
TOI
Q4 25
$5.5B
Q3 25
$5.6B
Q2 25
$5.8B
Q1 25
$5.6B
Q4 24
$5.4B
Q3 24
$5.8B
Q2 24
$5.7B
$9.9M
Q1 24
$5.7B
$29.8M
Stockholders' Equity
IBOC
IBOC
TOI
TOI
Q4 25
$3.3B
$-15.7M
Q3 25
$3.1B
$-12.3M
Q2 25
$3.0B
$-9.0M
Q1 25
$2.9B
$5.1M
Q4 24
$2.8B
$3.6M
Q3 24
$2.7B
$15.5M
Q2 24
$2.6B
$29.2M
Q1 24
$2.5B
$41.3M
Total Assets
IBOC
IBOC
TOI
TOI
Q4 25
$16.6B
$164.7M
Q3 25
$16.6B
$163.6M
Q2 25
$16.5B
$159.8M
Q1 25
$16.3B
$164.0M
Q4 24
$15.7B
$172.7M
Q3 24
$15.9B
$179.2M
Q2 24
$15.5B
$179.6M
Q1 24
$15.4B
$204.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBOC
IBOC
TOI
TOI
Operating Cash FlowLast quarter
$491.1M
$3.2M
Free Cash FlowOCF − Capex
$472.9M
$2.2M
FCF MarginFCF / Revenue
217.2%
1.5%
Capex IntensityCapex / Revenue
8.3%
0.7%
Cash ConversionOCF / Net Profit
4.59×
TTM Free Cash FlowTrailing 4 quarters
$809.9M
$-27.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBOC
IBOC
TOI
TOI
Q4 25
$491.1M
$3.2M
Q3 25
$115.2M
$-12.6M
Q2 25
$95.5M
$-10.2M
Q1 25
$140.5M
$-5.0M
Q4 24
$473.9M
$4.2M
Q3 24
$116.5M
$819.0K
Q2 24
$107.2M
$-15.7M
Q1 24
$135.4M
$-15.9M
Free Cash Flow
IBOC
IBOC
TOI
TOI
Q4 25
$472.9M
$2.2M
Q3 25
$112.2M
$-13.2M
Q2 25
$91.6M
$-11.4M
Q1 25
$133.1M
$-5.3M
Q4 24
$459.8M
$2.4M
Q3 24
$109.6M
$417.0K
Q2 24
$104.9M
$-17.5M
Q1 24
$128.9M
$-16.5M
FCF Margin
IBOC
IBOC
TOI
TOI
Q4 25
217.2%
1.5%
Q3 25
51.5%
-9.7%
Q2 25
44.0%
-9.5%
Q1 25
67.1%
-5.1%
Q4 24
220.8%
2.4%
Q3 24
51.7%
0.4%
Q2 24
50.5%
-17.7%
Q1 24
62.6%
-17.4%
Capex Intensity
IBOC
IBOC
TOI
TOI
Q4 25
8.3%
0.7%
Q3 25
1.3%
0.4%
Q2 25
1.9%
1.0%
Q1 25
3.7%
0.3%
Q4 24
6.8%
1.8%
Q3 24
3.3%
0.4%
Q2 24
1.1%
1.9%
Q1 24
3.2%
0.6%
Cash Conversion
IBOC
IBOC
TOI
TOI
Q4 25
4.59×
Q3 25
1.06×
Q2 25
0.95×
Q1 25
1.45×
Q4 24
4.12×
Q3 24
1.17×
Q2 24
1.11×
Q1 24
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBOC
IBOC

Segment breakdown not available.

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

Related Comparisons